Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
17 Outubro 2023 - 8:01AM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers, today announced the appointment of Scott
Garland to the company’s Board of Directors. Mr. Garland brings
more than 30 years of biopharmaceutical industry experience with
deep commercial and executive leadership expertise.
“We are delighted to have Scott join our Board of Directors at
such an exciting time for Olema,” said Sean P. Bohen, M.D., Ph.D.,
President and Chief Executive Officer of Olema Oncology. “His broad
experience on the frontlines of the biopharmaceutical industry,
leading the commercialization of groundbreaking therapies, will be
crucial as we enter the late-stage development of
palazestrant.”
Mr. Garland most recently served as CEO of PACT Pharma, an
immuno-oncology company that was focused on developing cell
therapies for solid tumors. Prior to PACT, Mr. Garland was
president and chief executive officer of Portola Pharmaceuticals
where he led the company through the commercial launch of Andexxa®
and a successful acquisition by Alexion. Before joining Portola, he
served first as chief commercial officer of Relypsa and then as
president of the U.S. organization after the company was acquired
by Vifor Pharma. Mr. Garland has held numerous other commercial
leadership roles at Exelixis (leading the launch of cabozantinib),
Genentech, Amgen, and Merck, including leading the commercial
franchises for two multi-billion-dollar therapies – Avastin® and
Rituxan®. Mr. Garland currently serves as a board member for ALX
Oncology and Day One Biopharmaceuticals. He received a B.S. from
California Polytechnic State University-San Luis Obispo and an MBA
from the Fuqua School of Business at Duke University.
“Olema is well along the path of advancing their mission to
transform the standard of care for women living with breast cancer,
and I am excited to contribute as palazestrant moves into Phase 3
and new pipeline assets are announced,” said Mr. Garland. “As Olema
continues to advance its pipeline, I believe that Olema’s science,
the management team’s track record of success, and its strong
financial foundation positions the company well to define the next
generation of targeted therapies for women’s cancers.”
“On behalf of Olema’s Board of Directors, I would like to
welcome Scott to the Board, and we look forward to benefiting from
his unique perspective and counsel as we navigate this pivotal
moment in Olema’s history,” Ian Clark, Chairman of Olema’s Board of
Directors.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, palazestrant (OP-1250), is
a proprietary, orally-available small molecule with dual activity
as both a complete estrogen receptor (ER) antagonist (CERAN) and a
selective ER degrader (SERD). It is currently being evaluated both
as a single agent in an ongoing Phase 2 clinical trial, and in
combination with CDK4/6 inhibitors (palbociclib and ribociclib) and
a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. Palazestrant has
been granted FDA Fast Track designation for the treatment of
ER+/HER2- metastatic breast cancer that has progressed following
one or more lines of endocrine therapy with at least one line given
in combination with a CDK4/6 inhibitor. Olema is headquartered in
San Francisco and has operations in Cambridge, Massachusetts. For
more information, please visit us at www.olema.com, or follow us on
Twitter and LinkedIn.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Words such as
“anticipate,” “expect,” “will,” “may,” “goal,” “potential” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These statements
include those related to the potential beneficial characteristics
of palazestrant (OP-1250), including the potential to become
best-in-class or transform the standard of care for women living
with ER+/HER2- metastatic breast cancers, the capabilities of
Olema’s executive management team and board of directors, the
clinical timeline and status for palazestrant, and Olema’s
preclinical and clinical pipeline. Because such statements deal
with future events and are based on Olema’s current expectations,
they are subject to various risks and uncertainties, and actual
results, performance or achievements of Olema could differ
materially from those described in or implied by the statements in
this press release. These forward-looking statements are subject to
risks and uncertainties, including, without limitation, those
discussed in the section titled “Risk Factors” in Olema’s Quarterly
Report on Form 10-Q for the quarter ended June 30, 2023, and future
filings and reports that Olema makes from time to time with the
U.S. Securities and Exchange Commission. Except as required by law,
Olema assumes no obligation to update these forward-looking
statements, including in the event that actual results differ
materially from those anticipated in the forward-looking
statements.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024